Press Releases from AFFiRiS AG (3 total)
AFFIRIS AG: Parkinson's Vaccine – Clinical Results Boost Prospects
VIENNA, Austria, September 07, 2016 — AFFiRiS AG announced today results of AFF008A, a Phase I clinical trial to assess boost immunizations with AFFITOPE® PD01A,…
AFFIRIS AG: Parkinson's Vaccine – Clinical Results Boost Prospects
Boost Vaccination Data Encourage Continued Development of AFFiRiS Therapeutic Parkinson's Disease Vaccine against Alpha-Synuclein
• PD01A was Safe and Well Tolerated: Primary Endpoint of Phase…
AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
Vienna, 27. May 2009. The atherosclerosis vaccine development program by AFFiRiS AG is receiving financial support from the EU's EUROTRANS-BIO call. The respective project is…
Go To Page:
